|
SocialPicks Sentiment:
N/A
** not enough data to be rated
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
From the Blogosphere
Stem Cell Stocks Update
|
|
|
Today, Monday, March 9, President Barack Obama will be signing an executive order to eliminate a ban on federal funding for embryonic stem-cell research. This major change in policy will cause the research into stem cell therapy to increase substantially. Research has been continuing to utilize stem cells for gene therapy and the treatment of Parkinson’s disease, heart disease, diabetes, multiple sclerosis, arthritis, and many other medical conditions.
Stem cells can come from embryos and from cord blood, the blood from umbilical cords, and even in baby teeth.
Alexion Pharmaceuticals...
|
Analysis of Stem Cell Index YTD
|
|
|
The accompanying table includes statistics for the 40 companies in the ETF Innovators Global Stem Cell and Regenerative Medicine Index, which is down 13.8% at a value of 3,387 from a 2/22/09 inception date value of 3,928.
The index is down 30.6% over the past year on an equal-weight basis, compared to losses of 31.2% for the Healthcare Sector SPDR (XLV), 19% for iShares Nasdaq Biotech (IBB), 14.7% for SPDR S&P Biotech (XBI), 29.7% for PowerShares Biotech & Genome (PBE), and 46.1% for the S&P 500 SPDR (SPY).
Below is a profile for each company, including a summary of their business and researc...
|
Global Stem Cell and Regenerative Medicine Index
|
|
|
The accompanying table (click to enlarge) includes 40 companies in the ETF Innovators Global Stem Cell and Regenerative Medicine Index, which represents an expansion of the Emerging Stem Cell Index I have written about previously. The expanded global index includes companies with market caps less than $1B at the index inception with a total market value of $3,814 as of the close today. As previously, I will track the total market value for a more comprehensive gauge of investor sentiment toward the space.
The index is down 16.2% over the past year on an equal-weight basis, compared to losses...
|
Stem Cell Index Down 7% in Past Week
|
|
|
The accompanying table (click to enlarge) includes 26 companies in the ETF Innovators Emerging Stem Cell Index, which lost 7% of its market value in the past week (at 1,148 today) and posted a 15.2% loss over the past year on an equal-weight basis.
Results for benchmark indexes and ETFs include gains of 1.5% for the Cosmetic and Restorative Medicine Index and losses of 1.2% for SPDR S&P Biotech (XBI), 18.7% for Healthcare Sector SPDR (XLV), 7.2% for iShares Nasdaq Biotech (IBB), and 17.7% for PowerShares Biotech & Genome (PBE).
The next catalyst expected for stem cell and regenerative medicin...
|
An Expanded Emerging Stem Cell Index
|
|
|
The accompanying table (click to enlarge) includes 32 companies in the ETF Innovators Emerging Stem Cell Index of U.S.-listed stocks with market caps below $250M. I will maintain the index with these 32 components and track the total market value and stock price changes as an indicator of investor and trader sentiment toward the stem cell and regenerative medicine space.
Below is a list of all 32 companies in descending order by market cap with a total value of $1.27B and an average stock price change of -15% over the past year for the index, as compared to losses of 20% for the Healthcare S...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Visit streetinsider.com
Be the first to start a discussion and earn 2 points.
More Resources
|
About Neuralstem Inc.
- Answers.com
